key: cord-0068491-conz6fug
authors: Kumar, M.; Danda, S.; Reddy, H.; S, J.; Paul, G.; Varkki, S.
title: 158: Late diagnosis of cystic fibrosis after first decade of life: Clinical observations of a milder phenotype in India
date: 2021-10-15
journal: J Cyst Fibros
DOI: 10.1016/s1569-1993(21)01583-6
sha: b66d7e91e3f80e1cc65015b7c69436b12e9f7a98
doc_id: 68491
cord_uid: conz6fug

nan

Background: C-reactive protein (CRP), a systemic marker of inflammation, has been proposed as a biomarker for pulmonary exacerbation (PEx) diagnosis and treatment response. CRP >75 mg/mL (log 10 CRP >1.875) has been associated with increased risk of PEx treatment failure. We interrogated CRP measures collected during the STOP2 PEx study (NCT02781610) of clinical response to different intravenous (IV) antimicrobial treatment durations as a PEx presentation and treatment response biomarker. Methods: The STOP2 study design has been reported in detail [1] . CRP measures were collected at IV antimicrobial treatment start (V1), randomization (V2, 7 to 10 days after treatment start), and 2 weeks post-treatment end (V3) and converted to log 10 values. Correlations between V1 log 10 CRP, log 10 CRP change from V1 to V3, and clinical responses (change in lung function as ppFEV 1 3]), but not by age subgroup. V1 log 10 CRP correlated somewhat with log 10 CRP change from V1 to V3 (r 2 = 0.255) but less so with V1 to V3 changes in ppFEV1 (r 2 = 0.016) or CRISS (r 2 = 0.031). Correlations of log 10 CRP changes from V1 to V3 with ppFEV1 and CRISS changes from V1 to V3 were modest (r 2 of 0.061 and 0.066, respectively). In all, 109/951 subjects (11.5%) had a V1 log 10 CRP >1.875 mg/L; mean V1 to V3 ppFEV1 and CRISS changes were significantly better for this group than those with log 10 CRP ≤1.875 mg/L ( ppFEV 1 response of 9.1 [7.0, 11.3] vs 6.1 [5.5, 6.8]; CRISS response of -24.6 [-26.6, -21.6] vs -17.6 [-18.6, -16.6]). Conclusion: V1 log 10 CRP concentrations varied widely at PEx diagnosis in the STOP2 study cohort. Correlations between log 10 CRP concentration changes from V1 to V3 and ppFEV1 and CRISS changes over the same period were very modest, suggesting that CRP change will have limited utility as a biomarker of PEx treatment response. A log 10 CRP of >75 mg/L at PEx diagnosis did not predict a worse lung function or symptom change from V1 to V3 (in fact, these subjects had significantly better mean treatment responses). Background: There is paucity of data on the prevalence, phenotype, and clinical outcome of patients with cystic fibrosis (CF) from the Indian subcontinent, specifically among those who were diagnosed after the first decade of life. In general, late diagnosis results in severe pulmonary and nutritional morbidity. We report data from a cohort of patients with CF (PwCF) focusing on those with a milder phenotype of CF disease despite late diagnosis. Methods: Retrospective chart review of PwCF followed at a tertiary medical center in India was conducted. Of the 63 newly diagnosed PwCF between May 2018 and December 2020, 18 were diagnosed after 10 years of age. Patient demographics, clinical outcomes, spirometry, nutritional parameters, and diagnostic data were reviewed. Results: Of the 18 patients, 11 were from India and 7 from Bangladesh. Median age was 16 years (range 10.5 − 23.4 years) and 10 (56%) were male. Overall, median age at which earliest symptom was reported was 1.9 years (range 0.1-15 years); however median age of diagnosis was 12 years (range 10.25-21.75). In the first decade, the majority did not report any recurrent CF-specific symptoms, and 3 patients reported only fatigue in summer. Sweat chloride levels were diagnostic in 9/18 (50%), in the indeterminate zone in 8, and normal in 1 patient. Family history of CF was noted in 27% of patients. CFTR sequencing with deletion/duplication was completed in 16 patients. None had homozygous F508del mutations; 4 patients were heterozygous for F508del and of these patients, 3 were pancreatic insufficient. Three patients were heterozygous for the intronic variant 3718-2477C >T ( previously reported from India); all 3 had normal or indeterminate sweat chloride levels and 2 were pancreatic sufficient. From a pulmonary perspective, 83% had respiratory symptoms with a mean FEV1% predicted of 61% (range 18-101%). Extensive bronchiectasis was noted in 77.8%. Three patients had no respiratory symptoms. Microbiologic cultures from sputum isolated Pseudomonas aeruginosa and Staphylococcus aureus in 66.7% and 55.6% respectively. Three patients had documented pulmonary tuberculosis, and atypical mycobacterium was isolated from 1 patient. Nasal polyps were noted in 16.7%. From a nutritional perspective, fecal elastase data was available in 16 patients, and 69% were pancreatic sufficient, 31% were pancreatic insufficient. Median body mass index (BMI) was 14.8 kg/m2 (range 11-25 kg/m 2 ), and at time of diagnosis 27% had BMI above the 25thpercentile. Four patients had CF-related diabetes. Conclusion: In the Indian subcontinent, PwCF diagnosed after 10 years of age had mild clinical phenotype in early childhood, often related to uncommon mutations. However, there is a trend toward significant decline in pulmonary disease in a few patients in the second decade. Proactive efforts to identify PwCF with milder phenotypes, including surveillance of siblings, would be important to prevent worsening pulmonary morbidity even though disease progression is gradual in the first decade. We report on 4 patients with cystic fibrosis who were infected with Sars-CoV-2 and the changes in FVC and FEV1. Methods: We retrospectively reviewed charts of CF patients at our center since the onset of the COVID pandemic to determine who had been infected with Sars-CoV-2. We then determined which patients had PFTs performed prior to and post infection. We assessed changes in FVC and FEV1 for these patients. Results: There were 9 patients (age 10 to 42 years) at our center identified as having been infected with Sars-CoV-2 from March 2020 to April 2021. Of these, 4 patients (age 21-40 years) had PFTs prior to and following Sars-CoV-2 infection. There were 3 of these patients being treated with elexacaftor/tezacaftor/ivacaftor as part of their routine care. One patient did receive monoclonal antibody therapy for his infection. Baseline FVC pp ranged from 78 to 97% predicted and baseline FEV1 pp ranged from 59 to 89% predicted. Sars-CoV-2 infection severity for all patients was mild, and no patients were hospitalized as a result of this infection. The percent change in FVC ( pre-to post-Sars-CoV-2) for all 4 patients was 1.5%, 10.5%, −7.7% and 0.9%. The percent change in FEV1 ( pre-and post-Sars-CoV-2) for all 4 patients was 0.8%, 5%, −2.4% and −0.4%. There was no significant change in the FVC and FEV1 from baseline values following Sars-CoV-2 infection for these 4 patients with mild infection (Table 1) . Table 1 . Sars-CoV-2 pre-and post-spirometry

Conclusion: This small case series of 4 adult patients with CF infected with Sars-CoV-2 noted no significant change in lung function following infection. The range in Sars-CoV-2 infection severity can vary between mild disease with no change in lung function to death. Based on CFF reports, it is recognized that outcomes may depend on baseline lung function and severity of lung disease, as well as if post-lung transplant.

Other factors may play a role in COVID-19 outcomes, including use of routine airway clearance, possible treatment with highly effective CFTR modulators, and outpatient therapies for Sars-CoV-2. Background: Using dynamic chest radiography (DCR), a unique real-time X-ray imaging system [1] , we have shown variation in diaphragm movement following pulmonary exacerbations (PEx) in adult people with CF (PwCF). Now, to assess the impact of PEx on tidal and deep breathing phases of respiratory physiology, we have utilized DCR to look at their effect on lung area changes. Methods: Twenty PwCF ([mean ± SD] age 25.2 ± 6.6 years, average ppFEV1 59.5 ± 17.1, BMI 21.1 ± 3.6kgm −2 , 14 female) underwent spirometry and DCR before and after inpatient treatment for PEx. Hemidiaphragm speed and change in vertical hemidiaphragm position were measured by DCR during tidal and deep breathing, to assess the impact of PEx on respiratory muscle function, with the posteroanterior projected lung area (PLA) measured as a surrogate for lung volume. Results: Treatment improved maximum excursion during tidal breathing of both left (12.9 ± 5.1 to 15.9 ± 6.6 mm, P = 0.01) and right (11.2 ± 5.2 to 14.5 ± 7.1 mm, P = 0.02) hemidiaphragms, as well as maximum tidal inspiratory speed (left 15.8 ± 5.0 to 18.6 ± 6.6 mm/s, P = 0.04; right 13.9 ± 5.1 to 16.5 ± 6.9 mm/s, P = 0.07). Hemidiaphragm excursion on deep breathing improved on the right (13.4 ± 6.7 to 18.3 ± 8.9 mm, P < 0.001) and left (18.2 ± 8.4 to 23.9 ± 9.5 mm, P = 0.01), as did maximum passive expiratory speed for right (12.0 ± 4.4 to 19.5 ± 10.4 mm/s, P = 0.003) and left (15.6 ± 8.4 to 22.6 ± 11.9 mm/s, P = 0.008) hemidiaphragms. The ratio between maximum inspiratory/expiratory PLA correlated with ppFEV1 (r = 0.753, P < 0.001). PLA at maximum expiration correlated with the FEV1/FVC ratio (left, r = −0.800, P < 0.001; right, r = −0.672, P < 0.001; Figure 1 ). Maximum hemidiaphragm excursion correlated with FVC (left, r = 0.6340, P < 0.001; right, r = 0.6927, P < 0.001). 

We have demonstrated improvement in diaphragm excursion and speed during tidal breathing, suggesting individuals are able to take deeper and faster tidal breaths as a result of treatment for PEx. The increase in passive expiratory speed following a deep breath matches our previous work and suggests improvement in the elastic recoil of the lungs. The correlation between spirometric and DCR parameters suggest DCR may be a complementary investigation in measuring lung function changes during PEx, especially in individuals in whom reproducible spirometry is difficult.

Dynamic chest radiography is a novel tool to assess chest wall and diaphragm dynamics during pulmonary exacerbations of cystic fibrosis